106 related articles for article (PubMed ID: 8912478)
1. Advances in supportive therapy.
Facchini T
Zentralbl Gynakol; 1996; 118(10):589-90. PubMed ID: 8912478
[No Abstract] [Full Text] [Related]
2. [Evaluation of efficacy and toxicity of PC chemotherapy (cisplatin, cyclophosphamide) administered with amifostine in patients with clinically advanced ovarian cancer].
Pawlicki M; Rolski J; Wiczyńska B; Rychlik U
Ginekol Pol; 1998 Jul; 69(7):580-5. PubMed ID: 9810418
[TBL] [Abstract][Full Text] [Related]
3. [Cytoprotective effect of Amifostine in the combined chemotherapy of advanced ovarian carcinoma].
Nagy P; Kádasi L
Orv Hetil; 2000 Sep; 141(37):2027-30. PubMed ID: 11037611
[TBL] [Abstract][Full Text] [Related]
4. A randomized trial of amifostine and carmustine-containing chemotherapy to assess lung-protective effects.
Jones RB; Stockerl-Goldstein KE; Klein J; Murphy J; Blume KG; Dansey R; Martinez C; Matthes S; Nieto Y
Biol Blood Marrow Transplant; 2004 Apr; 10(4):276-82. PubMed ID: 15077226
[TBL] [Abstract][Full Text] [Related]
5. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer.
Kemp G; Rose P; Lurain J; Berman M; Manetta A; Roullet B; Homesley H; Belpomme D; Glick J
J Clin Oncol; 1996 Jul; 14(7):2101-12. PubMed ID: 8683243
[TBL] [Abstract][Full Text] [Related]
6. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects.
Capizzi RL
Semin Oncol; 1999 Apr; 26(2 Suppl 7):72-81. PubMed ID: 10348264
[TBL] [Abstract][Full Text] [Related]
7. [Supportive enteral nutrition therapy in cytostatic drug treatment despite decreased absorptive ability of the small intestine].
Täubert D; Neises M; Wischnik A; Holm E
Gynakol Rundsch; 1991; 31 Suppl 2():291-3. PubMed ID: 1790956
[No Abstract] [Full Text] [Related]
8. Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine.
Sastry J; Kellie SJ
Pediatr Hematol Oncol; 2005; 22(5):441-5. PubMed ID: 16020136
[TBL] [Abstract][Full Text] [Related]
9. Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Children's Oncology Group study.
Marina N; Chang KW; Malogolowkin M; London WB; Frazier AL; Womer RB; Rescorla F; Billmire DF; Davis MM; Perlman EJ; Giller R; Lauer SJ; Olson TA;
Cancer; 2005 Aug; 104(4):841-7. PubMed ID: 15999362
[TBL] [Abstract][Full Text] [Related]
10. Amifostine and hematologic effects.
Sriswasdi C; Jootar S; Giles FJ
J Med Assoc Thai; 2000 Apr; 83(4):374-82. PubMed ID: 10808697
[TBL] [Abstract][Full Text] [Related]
11. [Comparative research on different treatment regimens in disseminated cancer of the ovaries].
Marinov L; Koĭnov K; Tsekova V; Velikova M
Akush Ginekol (Sofiia); 1987; 26(1):49-52. PubMed ID: 3592111
[No Abstract] [Full Text] [Related]
12. Dose intensive combination platinum and cyclophosphamide in the treatment of patients with advanced untreated epithelial ovarian cancer.
Shapiro JD; Rothenberg ML; Sarosy GA; Steinberg SM; Adamo DO; Reed E; Ozols RF; Kohn EC
Cancer; 1998 Nov; 83(9):1980-8. PubMed ID: 9806657
[TBL] [Abstract][Full Text] [Related]
13. Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head-and-neck cancer.
Machtay M; Rosenthal DI; Chalian AA; Lustig R; Hershock D; Miller L; Weinstein GS; Weber RS
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):72-7. PubMed ID: 15093901
[TBL] [Abstract][Full Text] [Related]
14. [The potentials of combined chemotherapy in disseminated ovarian cancer].
Gorbunova VA; Perevodchikova NI; Kozachenko VP; Ryzhakov VM; Marenich AF; Zhordania KI
Akush Ginekol (Mosk); 1991 Feb; (2):54-7. PubMed ID: 1907433
[No Abstract] [Full Text] [Related]
15. Chemoprotection in anticancer therapy: the emerging role of amifostine (WR-2721).
Kurbacher CM; Mallmann PK
Anticancer Res; 1998; 18(3C):2203-10. PubMed ID: 9703784
[TBL] [Abstract][Full Text] [Related]
16. Re: "Selenium as an element in the treatment of ovarian cancer in women receiving chemotherapy".
Petru E; Petru C; Benedicic Ch
Gynecol Oncol; 2005 Feb; 96(2):559; author reply 559-60. PubMed ID: 15661254
[No Abstract] [Full Text] [Related]
17. Nephrotic syndrome after cisplatin plus cyclophosphamide for ovarian carcinoma.
Beretta R; Cattaneo MT; Damiani E; Luchini S; Zucca E; Trabattoni A; Natale N
Cancer Treat Rep; 1986 Apr; 70(4):543-4. PubMed ID: 3698054
[No Abstract] [Full Text] [Related]
18. Trial of amifostine in autologous stem cell transplant.
Sastry P; Bhagwat R; Biswas G; Khadwal A; Narayanan P; Bakshi A; Parikh P
Bone Marrow Transplant; 2006 Jan; 37(1):117-8. PubMed ID: 16273114
[No Abstract] [Full Text] [Related]
19. Combined therapy with Ukrain and chemotherapy in ovarian cancer (case report).
Lohninger A; Korsh OB; Melnyk A
Drugs Exp Clin Res; 1996; 22(3-5):259-62. PubMed ID: 8899343
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of subcutaneous amifostine in minimizing radiation-induced toxicities in patients receiving combined-modality treatment for squamous cell carcinoma of the head and neck.
Law A; Kennedy T; Pellitteri P; Wood C; Christie D; Yumen O
Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1361-8. PubMed ID: 17869022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
